Bioverge Monthly — January 2017
Bioverge is an online venture capital firm and curated marketplace helping angel investors identify, fund, and support the most promising life science and healthcare technology startups.
Impact Investing. We believe that investing for the right reasons and having a positive impact on the world does not have to be mutually exclusive with generating an outsized financial return.
Access. Deep Screen. Diversification. Bioverge enables investors to diversify their existing portfolios with startup investment opportunities previously only accessible to venture capital firms. We do the heavy lifting for our investors. Bioverge opportunities are deep screened, each having attracted professional investment and undergone Dynamic Diligence. Within the platform, investors have access to tools for opportunity evaluation and company engagement, and can either invest in individual companies or in a multi-company fund.
Streamlined Capital. Resources. Community Access.
With a transparent process, Bioverge provides companies with streamlined access to capital and access to a healthcare-centered community of domain and technical experts, and connections to the Bioverge network of industry and downstream investment partners.
Notable Labs has partnered with Cancer Commons (a non-profit) to launch an adaptive, personalized medicine approach in relapsed and refractory pediatric leukemia! They are aiming to raise $50,000 for this initial pilot with Lucile Packard Children’s Hospital (Stanford), which would enable Notable to treat upwards of 10 patients, and will begin enrolling in 1Q 2017. If you or someone in your network would like to help find treatments for children with advanced leukemia, please consider donating! The CEO of Notable was also named to Forbes 30 Under 30 in Healthcare!
Echo Laboratories closed a $2M funding round in under two months! Originally estimated at $500K, the ceiling was raised with an increased momentum in the life sciences investor community, and was led by Tech Coast Angels. The funding amount was the largest in TCA’s 2016 portfolio of deals. At Bioverge, we are thrilled to participate in this financing and to count TCA as one of our syndication partners as we continue to build our community.
A Few of Our Favorite Stories
How to De-Risk a Startup. This post contains a (non-exhaustive) list of common startup-related risks, the spectra along which those risks might be classified, and some tips and heuristics for mitigation. The further you move from “high risk” to “low risk” along each spectrum, the stronger your valuation, perceived progress, and likelihood of success will become.
Biotech Venture Capital Mythbusting Redux. Like the overall venture capital asset class, biotech has also been strong over past few years: 2014–2016 will be the three largest years for private biotech funding since the start of data collection in 1995. On the public market front, even with the 30%+ correction since July 2015, we’ve continued to see significant IPO activity and will likely have over 30 biotech IPOs this year — a top quartile year for new issuances.
Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits (New York Times). Dr. Belldegrun, a physician, co-founded Kite Pharma, a company that could be the first to market next year with a highly anticipated new immunotherapy treatment. But even without a product, Dr. Belldegrun has struck gold. His stock in Kite is worth about $170 million. Investors have profited along with him, as the company’s share price has soared to about $50 from an initial price of $17 in 2014.
Will artificial intelligence help to crack biology? Silicon Valley has the worlds of biology and disease in its sights and believes that AI holds the key.
Outlook good for expanded accredited investor definition after strong approval in House. Under the reform bill, the accredited investor definition would encompass people with securities-related licenses, such as investment advisers and brokers, and those who have education or experience related to a particular investment, such as a doctor who wants to participate in a biomedical startup.
Join the Bioverge Community
Follow us on Twitter, LinkedIn, and Facebook! We post frequent updates and highlight relevant news and events. Please support us as we continue to grow our presence on social media.
Want to invest in the most promising curated life science and healthcare technology startups? Sign up to become a Bioverge Member and invest with us!